Why the study?
Current guidelines from hypertension and renal societies have issued conflicting blood pressure recommendations for patients with chronic kidney disease and hypertension, risking clinical confusion and less effective prevention.
Does tight blood pressure control reduce renal and cardiovascular outcomes in patients with chronic kidney disease and hypertension?
Does tight blood pressure control reduce renal and cardiovascular outcomes in patients with chronic kidney disease and hypertension?
Answers are grounded in this paper and cite their sources.
This review advocates for strict blood pressure targets (<130/80 mmHg generally, <120 mmHg in younger patients) to minimize renal and cardiovascular risk in patients with chronic kidney disease.
Hypertension affects over a billion people worldwide and is the leading cause of cardiovascular disease and premature death worldwide, as well as one of the key determinants of chronic kidney disease worldwide. People with chronic kidney disease and hypertension are at very high risk of renal outcomes, including progression to end-stage renal disease, and, even more importantly, cardiovascular outcomes. Hence, blood pressure control is crucial in reducing the human and socio-economic burden of renal and cardiovascular outcomes in those patients. However, current guidelines from hypertension and renal societies have issued different and sometimes conflicting recommendations, which risk confusing clinicians and potentially contributing to a less effective prevention of renal and cardiovascular outcomes. In this review, we critically appraise existing evidence and key international guidelines, and we finally formulate our own opinion that clinicians should aim for a blood pressure target lower than 130/80 in all patients with chronic kidney disease and hypertension, unless they are frail or with multiple comorbidities. We also advocate for an even more ambitious systolic blood pressure target lower than 120 mmHg in younger patients with a lower burden of comorbidities, to minimise their risk of renal and cardiovascular events during their lifetime.
No takes yet. Share an insight, caveat, or question.
Gentile et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: